Chronic Idiopathic Constipation (CIC) News and Research

RSS
Chronic Idiopathic Constipation (CIC) is defined as the chronic presence of constipation symptoms. It is called idiopathic because the cause of this type of constipation is unknown and it is not caused by underlying illness or medication.
Gas detecting electronic pill for diagnosis of gastrointestinal ailments

Gas detecting electronic pill for diagnosis of gastrointestinal ailments

FDA approves new oral medication for treating chronic idiopathic constipation in adult patients

FDA approves new oral medication for treating chronic idiopathic constipation in adult patients

Vibrating oral capsule for chronic constipation shows positive results

Vibrating oral capsule for chronic constipation shows positive results

Ironwood and Forest commence new DTC patient awareness campaign for LINZESS

Ironwood and Forest commence new DTC patient awareness campaign for LINZESS

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo receives supplement approval from FDA for AMITIZA

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Constipation drug may bring US patients relief

Constipation drug may bring US patients relief

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation

Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Sucampo submits marketing application for Amitiza drug

Sucampo submits marketing application for Amitiza drug

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint

Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint